|
In June 2000 scientists in America and the UK announced that they had completed the first rough draft of the human genetic code. Although it may be several years before the information is fully available for use by the scientific and medical communities, the next decades will probably see an explosion in the number of techniques that become available based on this research. As a society and as individuals we need to think fast so that we make good use of this phenomenal resource. Four molecules (bases), adenine (A), thymine (T), guanine (G), and cytosine (C) 'spell out' the genes on which all living things are built. While viruses only have around 200,000 bases, human beings have three thousand million. Surprisingly about 90 per cent of this seems to be inactive. The rest forms the sequence for the 50-100,000 genes. Genes give instructions that enable cells to build proteins. Errors in a gene's code can result in a faulty or absent protein. This can cause specific diseases or malformations, or it can increase a person's risk of succumbing to different illnesses. Changes in other genes are harmless and account for much individual variation. Some changes even protect individuals from certain diseases. While microscopes have enabled scientists to understand how micro-organisms and viruses cause disease, the science of molecular pathology is enabling us to define the molecular changes that occur in cells when we fall victim to disease. Clinical geneticists have already seen major changes in the quality of advice that they can give to families who seek their advice. During the next couple of decades, other specialities will feel the impact of these advances. Current applicationsMany single gene disorders have had their molecular errors identified and where these are straightforward, relatively simple diagnostic tests can be developed. For example, doctors can confirm that a boy has Duchenne muscular dystrophy by looking for specific genetic changes in cells collected in a simple blood sample. This avoids the need for an invasive muscle biopsy. In addition, his mother, aunts and sisters can be told whether they are carriers of the disease. For those who request it, there is also an accurate early pre-natal test. None of this was possible before the development of molecular testing. In another situation a family may find that some of its members have the mutation responsible for Hereditary Non-Polyposis Colon Carcinoma (HNPCC). Genetic tests can distinguish those who do or do not have the mutation. Those now known to be at a real risk are more motivated to attend monitoring sessions and resources can then be concentrated on them. At the same time, those without the mutation can be reassured and told that they do not need to be monitored. Molecular diagnostic tests are also being used for classifying tumours and micro-organisms. Potential new therapiesReplacing non-functional with functional genes in order to treat rare single gene disorders is the dream of gene therapy. However this is likely to take at least a few decades before it becomes established. Doctors have had limited success in using gene therapy to treat a few children who have severe immunodeficiency. The treatment is possible because they take some cells out of the patient, add a new gene to these cells and then return them. With other diseases, such as cystic fibrosis, there are enormous problems associated with getting new genes to the target cells. More progress has been made in genetically manipulating bacteria, yeast and mammals so that they produce valuable human proteins. The bacterial production of growth hormone, however, illustrates that this can introduce new dilemmas as well as benefits. Because manufactured growth hormone does not carry the risk of being contam-inated with the agent that causes Creutzfeldt-Jakob Disease, some parents of naturally short children are now asking for the hormone to 'enhance' their child's growth. More testsAttention is increasingly turning to common disorders such as asthma, hypertension and diabetes. All of these have a definite but complex genetic component. Researchers predict that there will probably be about 10 million normal variants within the human genome, some 200,000 of which will probably have some functional significance. A striking example is new variant Creutzfeldt-Jakob Disease. Scientists believe that the disease is acquired from cattle with bovine spongiform encephalopathy (BSE). Everyone builds prion proteins (PrP) in their brains and normal PrP does no harm. But so far, only people with a partic-ular common variant of the code at codon 129 on each of their two PrP genes have developed the disease. People with one version of the code in both of a person's genes for apolipoprotein E are at a greater risk than others of developing Alzhei-mer's disease. The link is not strong, but in the future it could become one of a handful of genes that make up a highly predictive assay. Also, prior to starting any drug treatment, a person's genetic profile might indicate which type of medication is most likely to succeed and which avoided because of genetic predisposition to side effects. For example, a person's response to medication commonly used to treat asthma is strongly influenced by a single base change in the gene that builds the drug's receptor. There are many other examples of this phenomenon, so it is easy to see why the pharmaceutical companies are pouring money into genome research. Dangers of genetic testsSimple diagnostic tests that seek to find out what is wrong in people who already know they are unwell are non-controversial. But when apparently healthy individuals are tested more thought is needed. the next generationHealthy people may be tested to see if they are at risk of having a child with a genetic disorder e.g. cystic fibrosis or, in the Jewish community, Tay Sachs disease. Advantages of such knowledge include being able to make informed decisions about child bearing, prenatal diagnosis or other options such as adoption. But it would be disastrous if testing, or even worse if prenatal detection and abortion, became compulsory or were driven by strong social pressure. viewing your futureFinding out what you might be affected by at some time in the future has benefits and detriments. People who find that they are at increased risk of diseases such as HNPCC can take steps to reduce their risk by careful surveillance and early surgery. On the other hand, testing for breast cancer genes is less satisfactory as current preventive measures are not always effective. With other disorders, such as Huntington's disease, there is no treatment or means of preventing the disease. Consequently many at risk individuals prefer not to know. In all these situations individuals are vulnerable to mental stress and depression. If the tests point to some risk, they may feel themselves undesirable as a marriage partner and have low self-esteem. They may also face the risk of stigmatisation and discrimination by employers, and insurance companies. Everyone considering testing should receive careful counselling before starting any test. Potential hazardsThe scenarios described above are relatively straightforward and can be handled by awareness and sensitive pre-test counselling, but what of future developments? We are already starting to identify genes and chromosomal regions associated with mental development, mental illness and personality traits. For example, children with William's syndrome have good social skills and enjoy company despite their learning difficulty. We now know that these children lack a small region of chromosome 7 indicating that genes in this area influence behaviour. Discovering the genetic basis for some of our personal and mental characteristics could cause us to become reductionist and see ourselves as completely controlled by our predetermined genetic make-up. Alternatively it could lead us to have a fatalistic outlook on life, particularly by those whose genetic make-up seems far less than optimal. With increased understanding of the genetic basis of disease and general characteristics such as height and intelligence, it might become possible to check for the genes in fertilised eggs, or even sperm and unfertilised eggs. This would give the ability deliberately to choose desirable or avoid undesirable characteristics. This is the concept of 'designer children'. It is not feasible at the moment, but we need to be aware of the possibility. More imminent is the possible use of genetically produced supplements to 'improve' healthy children. We need to distinguish carefully between treating sick people and 'enhancing' healthy ones. On occasions the dividing line will be unclear. Finally, we have the spectre of 'genetic cleansing' and an increasing intolerance by society of those with genetic imperfections. We must remember that we all have genetically-determined risk factors but in our current state of knowledge only some are known. Most remain hidden. Many diseases are multifactorial and don't depend only on our genes. The danger is that as a society we may decide that some imperfections are more undesirable than others. A Christian responseThese are new developments and ours is the first generation to be faced with making decisions on what is an appropriate use of the technology, what should be permitted and what banned. But in spite of the newness of the problems we do have fundamental and timeless principles that we can apply. They include:
ConclusionsThese four guiding principles give us signposts, but we will still have difficult decisions to face when they come into conflict with one another and priorities have to be decided. Those drawing up legislation in particular need insight and wisdom. Francis Collins is Director of the National Genome Research Institute of the USA. He is a committed Christian and spoke at a recent conference of Christians in Science, saying that Christians should marvel at the elegance and beauty of the genome and pray for a resurgence of faith in the scientific and medical communities. Without this he found it difficult to see how we are going to negotiate these troubled waters. Caroline Berry is a retired Consultant Geneticist
Copyright ©2002 Christian Medical Fellowship. |
|
|||||||||||||||||||||||||||||||